Tirzepatide (TZP), the first approved dual glucagon-like peptide 1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) agonist, has shown neuroprotective effects in preclinical models and early observational studies. This review maps and appraises current preclinical and clinical evidence on TZP's potential neuroprotective effects in neurodegenerative diseases (Alzheimer's and Parkinson's disease),...
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this scoping review covers neuroprotection broadly and has no direct audiology or hearing-health application at this time.
While GLP-1 receptor agonists are an area of growing neuroscience interest, this scoping review does not address auditory neuroprotection or ototoxicity, and offers no current implications for audiology practice.
- 01Scoping review covers Tirzepatide, a dual GIP/GLP-1 receptor agonist drug approved for diabetes and obesity.
- 02Reviews preclinical (lab and animal) and clinical trial evidence for neuroprotective (brain-protecting) effects.
- 03No audiology or hearing-health focus identified in the article.
- 04Published in Brain and Behavior.
- 05Potential future relevance if neuroprotective effects are studied in auditory pathways.
- PMID
- 42608956
- DOI
- 10.1002/brb3.71702.
- Journal
- Brain and Behavior
- Publication type
- review
- Evidence level
- 1a
- Population
- Preclinical models and human clinical trial participants across various neurological conditions
- Intervention
- Tirzepatide (dual GIP/GLP-1 receptor agonist)
Primary outcomes
Neuroprotective effects across preclinical and clinical contexts